Artificial Heart Takes Major Step Towards US Market

Paris, France-based Carmat is now a beat closer to bringing its total artificial heart to the U.S. market.

FDA gave Carmat conditional approval to initiate the second cohort of its early feasibility study with the Aeson artificial heart in the United States. The company has been developing the device for years, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure.